These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. ACR Appropriateness Criteria ; Coakley FV; Oto A; Alexander LF; Allen BC; Davis BJ; Froemming AT; Fulgham PF; Hosseinzadeh K; Porter C; Sahni VA; Schuster DM; Showalter TN; Venkatesan AM; Verma S; Wang CL; Remer EM; Eberhardt SC J Am Coll Radiol; 2017 May; 14(5S):S245-S257. PubMed ID: 28473080 [TBL] [Abstract][Full Text] [Related]
25. ACR Appropriateness Criteria® definitive therapy for early-stage cervical cancer. Small W; Strauss JB; Jhingran A; Yashar CM; Cardenes HR; Erickson-Wittmann BA; Gullett N; Kidd E; Lee LJ; Mayr NA; Moore D; Puthawala AA; Rao GG; Varia MA; Wahl AO; Wolfson AH; Yuh W; Gaffney DK Am J Clin Oncol; 2012 Aug; 35(4):399-405. PubMed ID: 22810416 [TBL] [Abstract][Full Text] [Related]
26. A systematic overview of radiation therapy effects in prostate cancer. Nilsson S; Norlén BJ; Widmark A Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499 [TBL] [Abstract][Full Text] [Related]
27. ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck. Koyfman SA; Cooper JS; Beitler JJ; Busse PM; Jones CU; McDonald MW; Quon H; Ridge JA; Saba NF; Salama JK; Siddiqui F; Smith RV; Worden F; Yao M; Yom SS Head Neck; 2016 Feb; 38(2):175-82. PubMed ID: 26791005 [TBL] [Abstract][Full Text] [Related]
28. ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. ; Yeung AR; Garg MK; Lawson J; McDonald MW; Quon H; Ridge JA; Saba N; Salama JK; Smith RV; Yom SS; Beitler JJ; Head Neck; 2012 May; 34(5):613-6. PubMed ID: 22250010 [TBL] [Abstract][Full Text] [Related]
29. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. Daly T World J Urol; 2020 Mar; 38(3):565-591. PubMed ID: 30850855 [TBL] [Abstract][Full Text] [Related]
30. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191 [TBL] [Abstract][Full Text] [Related]
31. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Cox JD; Gallagher MJ; Hammond EH; Kaplan RS; Schellhammer PF J Clin Oncol; 1999 Apr; 17(4):1155. PubMed ID: 10561174 [TBL] [Abstract][Full Text] [Related]